Biodexa Pharmaceuticals Appoints Fiona Sharp as Chief Financial Officer and Director

summarizeSummary

Biodexa Pharmaceuticals Plc has appointed Fiona Sharp, previously Group Financial Controller, as its new Chief Financial Officer and a member of the Board of Directors, effective January 5, 2026.

check_boxKey Events

• New Chief Financial Officer Appointed

  Fiona Sharp has been appointed as the Company's Chief Financial Officer and Corporate Secretary, effective January 5, 2026.

• Joins Board of Directors

  Ms. Sharp will also serve as a member of the Board of Directors.

• Internal Promotion

  Ms. Sharp previously served as Group Financial Controller of the Company since December 2019, indicating a seamless transition.

• Leadership Restructuring

  Stephen Stamp, who previously held the CFO and Corporate Secretary roles, will continue as Chief Executive Officer.

auto_awesomeAnalysis

Biodexa Pharmaceuticals Plc has strengthened its executive leadership by appointing Fiona Sharp as Chief Financial Officer and Corporate Secretary, who will also join the Board of Directors. Ms. Sharp's internal promotion from Group Financial Controller, a role she held since 2019, signals continuity and a smooth transition in financial oversight. This move is particularly important for a micro-cap company, as it solidifies financial governance and provides dedicated leadership for critical financial operations, while the former CFO, Stephen Stamp, remains as CEO.